Alternative splicing and alternative polyadenylation define tumor immune microenvironment and pharmacogenomic landscape in clear cell renal carcinoma.

Zhong, Weimin; Wu, Yulong; Zhu, Maoshu; Zhong, Hongbin; Huang, Chaoqun; Lin, Yao; Huang, Jiyi

Zhong, Weimin; Wu, Yulong; Zhu, Maoshu; Zhong, Hongbin; Huang, Chaoqun; Lin, Yao; Huang, Jiyi.

Afiliação

Zhong W; Central Laboratory at The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, China.
Wu Y; Department of Urology at The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, China.
Zhu M; Central Laboratory at The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, China.
Zhong H; Department of Nephrology at The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, China.
Huang C; Central Laboratory at The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, China.
Lin Y; Central Laboratory at The Second Affiliated Hospital of Fujian Traditional Chinese Medical University, Innovation and transformation center, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
Huang J; Department of Nephrology at The Fifth Hospital of Xiamen, Xiamen 361101, Fujian Province, China.

Mol Ther Nucleic Acids ; 27: 927-946, 2022 Mar 08.

Article em En | MEDLINE | ID: mdl-35211354

Palavras-chave

alternative polyadenylation; alternative splicing; clear cell renal carcinoma; immunotherapy; prognosis; tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Mol Ther Nucleic Acids Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google